Last reviewed · How we verify
Atrasentan low dose group
Endothelin receptor antagonist
Endothelin receptor antagonist Used for Pulmonary arterial hypertension.
At a glance
| Generic name | Atrasentan low dose group |
|---|---|
| Sponsor | AbbVie (prior sponsor, Abbott) |
| Drug class | Endothelin receptor antagonist |
| Target | Endothelin receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
Atrasentan works by selectively blocking the endothelin receptor, which is involved in the regulation of blood pressure and vascular tone.
Approved indications
- Pulmonary arterial hypertension
Common side effects
- Edema
- Fatigue
- Nausea
Key clinical trials
- Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With Atrasentan (PHASE2)
- A Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With Nephropathy (PHASE2)
- Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Atrasentan low dose group CI brief — competitive landscape report
- Atrasentan low dose group updates RSS · CI watch RSS
- AbbVie (prior sponsor, Abbott) portfolio CI